![](https://investorshub.advfn.com/uicon/102211.png?cb=1719302007)
Wednesday, November 10, 2021 2:46:18 PM
Here's my (highly educated) guess:
I emphasize that this is NOT a real PR (yet), just my speculation:
"Innovation Pharmaceuticals announces results of Phase II study of brilacidin in COVID-19
Analysis of the top lines results of this 120 patient study of brilacidin plus Standard of Care versus placebo and Standard of Care has now been completed.
Encouragingly, brilacidin proved effective in a number of patients hospitalized with COVID-19. However these results failed to reach significance.
This failure to reach significance was due to a more robust and pronounced effect in the placebo group than was anticipated, and therefore the study was not sufficiently powered to produce a statistically significant result. Additionally the requirement to use a lower dose of brilacidin than that used in previous Phase II studies resulted in lower serum levels than perhaps were necessary.
However retrospective analyses of some patient sub-sets have revealed some promising and encouraging directions for future research. For example, one-legged patients from Minsk not requiring ventilator support did better on brilacidin than on placebo.
Investigation of these promising avenues will require a Phase IIB clinical trial program and we are in the process of discussions with various entities regarding funding for this program."
"Nobody ever went broke underestimating the intelligence of the
American public."
H. L. Mencken
"It’s easier to fool people than to convince them that they have been fooled."
Anon
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM